Avionco Overview

  • Founded
  • 2010
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $500K
Latest Deal Amount
  • Investors
  • 2

Avionco General Information


Developer of novel cancer drugs designed to treat disease models relevant to cancer in humans. The company's drugs aim to make a contribution to the development of the Russian pharmaceutical industry through running experiments using specialized equipment for identifying the anti-tumour activity of drug candidates, enabling the cancer patients to improve the quality of life by creating new generation drugs and medication.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Primary Office
  • Street Rabochaya, 2a, Building 1
  • Khimki, Moscow 141400
  • Russia
+7 8 (000) 000-00-00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avionco Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 09-Jun-2010 $500K Completed Startup
1. Early Stage VC Completed Startup

Avionco Executive Team (1)

Name Title Board Seat Contact Info
Ruben Karapetyan Chief Scientific Officer & Director

Avionco Investors (2)

To view Avionco‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
FASIE Limited Partner 000 0000 000000 0
Torrey Pines Investment Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial